Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 10/20 | 0.63 |
| ▸ | KDR | P35968 | 9/20 | 0.63 |
| ▸ | LCK | P06239 | 9/20 | 0.63 |
| ▸ | SRC | P12931 | 4/20 | 0.63 |
| ▸ | HCK | P08631 | 9/20 | 0.51 |
| ▸ | FLT3 | P36888 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7853088 | 0.92 | TEK (0.62) | TEKKDRLCKSRCHCK | |
| SCHEMBL7855241 | 0.88 | TEK (0.63) | TEKKDRLCKSRCHCK | |
| SCHEMBL7852094 | 0.87 | TEK (0.62) | TEKKDRLCKSRCHCK | |
| SCHEMBL7852443 | 0.87 | TEK (0.66) | TEKKDRLCKSRCHCK | |
| SCHEMBL7852446 | 0.87 | TEK (0.66) | TEKKDRLCKSRCHCK | |
| SCHEMBL7843781 | 0.87 | TEK (0.59) | TEKKDRLCKSRCHCK | |
| SCHEMBL7853258 | 0.87 | TEK (0.61) | TEKKDRLCKSRCHCK | |
| SCHEMBL7842851 | 0.86 | TEK (0.60) | TEKKDRLCKSRCHCK | |
| SCHEMBL7850701 | 0.85 | TEK (0.64) | TEKKDRLCKSRCHCK | |
| SCHEMBL7850705 | 0.85 | TEK (0.64) | TEKKDRLCKSRCHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| CN-1335849-A | Pyrrolopyrimidines as protein kinase inhibitors | BASF AG (DE) | 2002-02-13 | — | — | CN | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | TEK 1465/4885KDR 3981/4885LCK 1/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | TEK 22/4885KDR 23/4885LCK 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.